LULU:NASDAQlululemon athletica inc. Analysis
Data as of 2026-03-11 - not real-time
$166.43
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Lululemon (LULU) is trading at $166.43, well below its 20‑day SMA of 177.35 and markedly under the 50‑day (188.06) and 200‑day (200.27) averages, indicating a bearish price trend. The RSI of 36.4 suggests momentum is moving out of oversold territory but still weak, while the MACD line sits below its signal line, reinforcing the bearish technical outlook. Volatility remains high at 44% over the past 30 days and beta of 1.22 points to a stock that moves more than the market, amplifying short‑term risk. Fundamentally, the company posts a low trailing P/E of 11.6, a strong ROE of 41%, and a healthy operating margin of 17%, yet the DCF fair value of $134.40 implies the current price is overvalued relative to intrinsic estimates. Recent news highlights the launch of a novel sweat‑concealing technology and heightened investor search interest, but the stock fell 1.96% after guidance that Q4 results would be at the high end of expectations, suggesting market skepticism. The balance sheet shows modest cash of $1.04 bn against $1.76 bn of debt, and free cash flow remains positive, supporting the company’s ability to fund growth initiatives. While the upside/downside metric shows a 24.8% potential upside, this appears driven by historical highs rather than forward fundamentals. Overall, the blend of solid earnings, low valuation multiples, and brand innovation offers a longer‑term investment case, but short‑term price pressure and heightened volatility warrant caution.
Investors should weigh the bearish technical signals and elevated risk metrics against the company’s strong profitability and growth narrative. In the near term, the stock may face further downside pressure, but a medium‑to‑long‑term horizon could capture value as the brand capitalizes on new product launches and global expansion.
Investors should weigh the bearish technical signals and elevated risk metrics against the company’s strong profitability and growth narrative. In the near term, the stock may face further downside pressure, but a medium‑to‑long‑term horizon could capture value as the brand capitalizes on new product launches and global expansion.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Price below all major moving averages
- Bearish MACD and low RSI
- High short‑term volatility
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Strong operating margins and ROE
- Low P/E relative to peers
- Continued product innovation
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Brand strength and global expansion potential
- Solid cash flow generation
- Blend of growth prospects and reasonable valuation
Key Metrics & Analysis
Financial Health
Revenue Growth7.10%
Profit Margin15.72%
P/E Ratio11.6
ROE41.02%
ROA20.29%
Debt/Equity39.16
P/B Ratio4.4
Op. Cash Flow$1.9B
Free Cash Flow$884.9M
Technical Analysis
TrendBearish
RSI36.4
Support$163.45
Resistance$192.49
MA 20$177.35
MA 50$188.06
MA 200$200.27
MACDBearish
VolumeIncreasing
Fear & Greed Index76.91
Valuation
Fair Value$134.40
Target Price$207.70
Upside/Downside24.80%
GradeFair
TypeBlend
Risk Assessment
Beta1.22
Volatility44.04%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.